Being A Successful Trader Just Got Easier…
From 10x Trading Champion Chuck Hughes comes the e-book helping thousands to survive the bear market, “Options trading Made Easy”!

Already full of tools and strategies for success, each copy now comes with a daily Trade of the Day, straight from Chuck to you!

Download your copy now!
>>>
John D. Young, insider at Pfizer

John D. Young Insider Information

Insider of Pfizer
John Young is Group President at Pfizer Inc., and is a member of the Company’s Executive Leadership Team.

Prior to this role, John was the Group President of Pfizer Innovative Health, which included six business units: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines and Consumer Healthcare; each business unit focused on developing innovative medicines and vaccines to make a meaningful difference to patients impacted by diseases with significant unmet need. John was also responsible for these businesses in Emerging Markets focused on increasing access to Pfizer’s innovative medicines to people across developing countries in Latin America, Asia, Africa and the Middle East.

Previously, John was the Group President for Pfizer Essential Health where he oversaw a broad portfolio of more than 600 products with a global reach in 160 countries. A scientist by training, John has more than 30 years of experience with Pfizer and has held a number of senior positions across the organization.

John is a member of the Board of Directors of the Consumer Healthcare Joint Venture with GlaxoSmithKline plc, and also Johnson Controls International (JCI). He serves on the Board of BIO (Biotechnology Innovation Organization) and as a member of the UK Government bioscience working group, the Life Sciences Council.

John holds a BSc in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School. He is married with three daughters.

What is John D. Young's net worth?

The estimated net worth of John D. Young is at least $10.48 million as of May 10th, 2016. Mr. Young owns 200,399 shares of Pfizer stock worth more than $10,482,872 as of July 4th. This net worth evaluation does not reflect any other assets that Mr. Young may own. Additionally, Mr. Young receives a salary of $4,250,000.00 as Insider at Pfizer. Learn More about John D. Young's net worth.

How old is John D. Young?

Mr. Young is currently 57 years old. There are 7 older executives and no younger executives at Pfizer. The oldest executive at Pfizer is Mr. Frank A. D'Amelio, CFO & Exec. VP, who is 64 years old. Learn More on John D. Young's age.

What is John D. Young's salary?

As the Insider of Pfizer Inc., Mr. Young earned a total compensation package of $8,989,193.00 in 2020. Mr. Young earned a salary of $1,285,000.00, stock awards of $1,814,734.00, options awards of $2,087,062.00, non-equity compensation of $1,800,000.00, and other compensation of $450,994.00.There are 4 executives that earn more than Mr. Young. The highest earning executive at Pfizer is Dr. Albert Bourla D.V.M., DVM, Ph.D., Chairman & CEO, who commands a salary of $11,070,000.00 per year. Learn More on John D. Young's salary.

How do I contact John D. Young?

The corporate mailing address for Mr. Young and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on John D. Young's contact information.

Has John D. Young been buying or selling shares of Pfizer?

John D. Young has not been actively trading shares of Pfizer during the last quarter. As an example of a recent trade by , 0 shares of the stock in a transaction dated Monday, July 4th. Learn More on John D. Young's trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Frank D'Amelio (EVP), Jennifer Damico (SVP), Jennifer Damico (SVP), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 276,647 shares worth more than $14,190,373.18. The most recent insider tranaction occured on June, 7th when SVP Jennifer B Damico sold 4,218 shares worth more than $227,603.28. Insiders at Pfizer own 0.1 % of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 6/7/2022.

John D. Young Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2021Sell150,000$50.06$7,509,000.00View SEC Filing Icon  
5/10/2016Sell41,700$33.53$1,398,201.00200,399View SEC Filing Icon  
11/7/2014Sell21,600$29.89$645,624.00View SEC Filing Icon  
See Full Table

John D. Young Buying and Selling Activity at Pfizer

This chart shows John D Young's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $52.31
Low: $51.25
High: $52.37

50 Day Range

MA: $50.66
Low: $46.53
High: $53.99

2 Week Range

Now: $52.31
Low: $38.93
High: $61.71

Volume

16,143,200 shs

Average Volume

29,302,072 shs

Market Capitalization

$293.51 billion

P/E Ratio

12.00

Dividend Yield

3.06%

Beta

0.73
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.